Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;7(6):117.
doi: 10.21037/atm.2018.09.26.

A real-world study on adverse drug reactions to Xuebijing injection: hospital intensive monitoring based on 93 hospitals (31,913 cases)

Rui Zheng  1 , Hui Wang  2 , Zhi Liu  2 , Xiaohui Wang  3 , Jing Li  3 , Xiang Lei  3 , Yilin Fan  4 , Si Liu  5 , Zhiqiao Feng  5 , Hongcai Shang  1   6
Affiliations

A real-world study on adverse drug reactions to Xuebijing injection: hospital intensive monitoring based on 93 hospitals (31,913 cases)

Rui Zheng et al. Ann Transl Med. 2019 Mar.

Abstract

Background: Although we have made tremendous medical advances in recent decades in modern antibiotics and supportive therapies, the treatment of sepsis has not experienced such rapid advancement. Xuebijing injection (XBJ) is a Chinese prescription consisting of Carthamus tinctorius, Radix paeoniae rubra, Ligusticum wallichii, Radix salviae miltiorrhizae and Radix angelicae sinensis. Clinical experience suggests that XBJ may provide a solution in the management of sepsis. However, the safety of this treatment is still controversial. This study aims to detect the occurrence of XBJ-related adverse drug reactions (ADRs) among individuals in clinical practice.

Methods: From the clinical application of XBJ in a real-world setting, patients in 93 hospitals using XBJ were monitored between August 2013 and August 2016. There was no limit on the treatment course and dosage. From data obtained in interviews or telephone follow-ups with hospitalized patients, the circumstances of patients' adverse events (AEs) during the course of drug treatment and during the 7 days after drug withdrawal were recorded and encoded by MedDRA18.0. The likelihood of ADRs was determined by the criteria of the Uppsala Monitoring Centre. Statistical analyses were performed by SAS9.2 software.

Results: In total, 31,913 participants enrolled, and none were lost to follow-up. AEs (suspected ADRs) occurred in 234 participants. ADRs occurred in 96 participants, and the incidence was 0.3%. The ADRs with the top three frequencies were skin pruritus (0.116%), erythra (0.066%) and chest tightness (0.044%). There was no significant relationship between ADRs and solvents (P=0.149), route of administration (P=0.640), unhealthy addiction (P=0.069), allergy (P=0.535), first use of XBJ (P=0.161) or dosage (P=0.743). There was a significant relationship between ADRs and irrigating syringe (P<0.0001) and fluid dripping too quickly (P=0.019).

Conclusions: This large-scale survey of hospitalized patients found that the incidence of ADRs was occasional (0.3%), while most of the ADRs were relatively mild or non-serious. XBJ should be administered rationally and according to its instructions to prevent the occurrence of ADRs.

Keywords: Adverse drug reaction (ADR); Xuebijing injection (XBJ); hospital intensive monitoring (HIM); real-world study.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: S Liu and ZQ Feng are employees of Chase Sun Pharmaceuticals. The other authors have no conflicts of interest to declare.

References

    1. Society of Critical Care Medicine CMA Chinese guidelines for the treatment of severe sepsis/septic shock (2014). Clinical Education of General Practice 2015;13:365-7.
    1. Zuo L, Sun Z, Hu Y, et al. Rapid determination of 30 bioactive constituents in XueBiJing injection using ultra high performance liquid chromatography-high resolution hybrid quadrupole-orbitrap mass spectrometry coupled with principal component analysis. J Pharm Biomed Anal 2017;137:220-8. 10.1016/j.jpba.2017.01.024 - DOI - PubMed
    1. Yin Q, Li C. Treatment Effects of Xuebijing Injection in Severe Septic Patients with Disseminated Intravascular Coagulation. Evid Based Complement Alternat Med 2014;2014:949254. 10.1155/2014/949254 - DOI - PMC - PubMed
    1. Liu SH, Chuang WC, Lam W, et al. Safety Surveillance of Traditional Chinese Medicine: Current and Future. Drug Saf 2015;38:117-28. 10.1007/s40264-014-0250-z - DOI - PMC - PubMed
    1. Lei Z. Adverse reactions with Xuebijing injection in 4 Cases Chin Hosp Pharm J 2015;35:471-72.